Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder
Thien Thanh Dang-Vu, Jean-François Gagnon, Mélanie Vendette, et al.
Neurology 2012;79;2302; Published online before print October 31, 2012;
DOI 10.1212/WNL.0b013e318278b658

This information is current as of April 10, 2013

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://www.neurology.org/content/79/24/2302.full.html

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2012 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder

ABSTRACT

Objectives: Patients with idiopathic REM sleep behavior disorder (IRBD) are at risk for developing Parkinson disease (PD) and dementia with Lewy bodies (DLB). We aimed to identify functional brain imaging patterns predicting the emergence of PD and DLB in patients with IRBD, using SPECT with $^{99m}$Tc-ethylene cysteinate dimer (ECD).

Methods: Twenty patients with IRBD were scanned at baseline during wakefulness using $^{99m}$Tc-ECD SPECT. After a follow-up of 3 years on average, patients were divided into 2 groups according to whether or not they developed defined neurodegenerative disease (PD, DLB). SPECT data analysis comparing regional cerebral blood flow (rCBF) between groups assessed whether specific brain perfusion patterns were associated with subsequent clinical evolution. Regression analysis between rCBF and clinical markers of neurodegeneration (motor, color vision, olfaction) looked for neural structures involved in this process.

Results: Of the 20 patients with IRBD recruited for this study, 10 converted to PD or DLB during the follow-up. rCBF at baseline was increased in the hippocampus of patients who would later convert compared with those who would not ($p < 0.05$ corrected). Hippocampal perfusion was correlated with motor and color vision scores across all IRBD patients.

Conclusions: $^{99m}$Tc-ECD SPECT identifies patients with IRBD at risk for conversion to other neurodegenerative disorders such as PD or DLB; disease progression in IRBD is predicted by abnormal perfusion in the hippocampus at baseline. Perfusion within this structure is correlated with clinical markers of neurodegeneration, further suggesting its involvement in the development of presumed synucleinopathies. Neurology® 2012;79:2302-2306

GLOSSARY

DLB = dementia with Lewy bodies; DSM-IV-TR = Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision; ECD = ethylene cysteinate dimer; FM = Farnsworth-Munsell; FWHM = full width at half maximum; IRBD = idiopathic REM sleep behavior disorder; MCI = mild cognitive impairment; MSA = multiple system atrophy; PD = Parkinson disease; RBD = REM sleep behavior disorder; RBDEv = REM sleep behavior disorder with clinical evolution; RBDSt = state of isolated REM sleep behavior disorder; rCBF = regional cerebral blood flow; UPDRS = Unified Parkinson Disease Rating Scale; UPSIT-12 = University of Pennsylvania Smell Identification Test 12 Items.

Idiopathic REM sleep behavior disorder (IRBD)—a condition characterized by dream-enactment behaviors—is frequently associated with the subsequent development of other presumed synucleinopathies: Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The physiopathology underlying this association remains unclear.

Some studies have attempted to identify biomarkers predictive of an evolution toward PD, DLB, or MSA. For instance, patients with IRBD who would evolve had worse baseline scores for olfaction and color vision than those who would remain stable. In addition, transcranial ultrasound of substantia nigra and dopaminergic imaging show promise as predictors of evolution.
In this study, we aimed to characterize the brain perfusion patterns at baseline that predicted future evolution from isolated IRBD to other neurodegenerative diseases, using SPECT with $^{99m}$Tc-ethylene cisteinate dimer (ECD). Because previous $^{99m}$Tc-ECD SPECT studies in patients with IRBD highlighted perfusion changes in the pons, striatum, and hippocampus, as well as neocortical areas (frontal, temporoparietal), we hypothesized that patterns predictive of the conversion would be part of these structures.

**METHODS** Subjects. Patients had an interview with a sleep specialist and a polysomnographic recording at the Sacré-Coeur Hospital to confirm the diagnosis of REM sleep behavior disorder (RBD). All patients discontinued psychotropic medications for the study. Their neurologic evaluation included a motor assessment with the Unified Parkinson Disease Rating Scale (UPDRS)-III, color vision discrimination by the Farnsworth-Munsell (FM)-100 test, and olfactory identification by the University of Pennsylvania Smell Identification Test 12 items (UPST-12). Exclusion criteria were psychiatric condition or dementia according to DSM-IV-TR and neuropsychological assessment, Mini-Mental State Examination score $<$ 26, and other sleep and neurologic disorders. Twenty patients with IRBD met the criteria for inclusion; 12 of them were also part of a previous study. Neurologic, neuropsychological, and SPECT assessments were performed during the same week. Although all IRBD patients were free of PD, DLB, and MSA at the time of scanning (baseline), 13 of them had mild cognitive impairment (MCI). Patients were then followed up annually during an average period of 3 years for detection of signs suggestive of a conversion to PD, DLB, or MSA. Ten healthy subjects, matched for age and gender, were submitted to a similar experimental procedure.

Standard protocol approvals, registrations, and patient consents. The protocol was approved by the Ethics Committee of the Sacré-Coeur Hospital–University of Montreal, and all participants signed a written consent form to participate.

SPECT data acquisition and analysis. SPECT scans with $^{99m}$Tc-ECD were performed in a 3-headed SPECT scanner (PRISM system, Picker Co.) in the morning during resting wakefulness (40 projections by scanner head, matrix of $128 \times 128$).

After reconstruction (filtered back projection, Butterworth filter, order: 8, cut-off: 0.39 FWHM [full width at half maximum], subtraction of 40% of the Compton window from the peak window) and attenuation correction (noniterative Chang algorithm, 0.15 cm$^{-1}$), SPECT data were processed in Statistical Parametric Mapping 8. All studies were registered and normalized to a SPECT template and smoothed with a 14-mm FWHM filter. Global normalization was performed using proportional scaling. Gray matter threshold was set at 1.0. Differences of regional cerebral blood flow (rCBF) between groups were assessed using a 2-sample $t$ test. Correlations between rCBF and clinical scores (UPDRS-III, FM-100, and UPST-12; at baseline) were assessed across all included patients (except one, because of incomplete clinical scores). In contrast to a previous study, clinical scores were entered in the same design matrix to ensure correlations were independent of other variables. Age and disease duration were included in the regression model. Statistical thresholds were set at $p < 0.05$ after correction for multiple comparisons on small volumes (sphere, 10 mm). Significant results were overlaid on an MRI template for localization of rCBF changes.

**RESULTS** Demographic and clinical variables of IRBD patients are presented in table e-1 on the Neurology® Web site at www.neurology.org. Of 20 patients, 10 showed clinical evolution within the follow-up period (RBDEv): 5 were diagnosed with PD, and the other 5 with DLB. The 10 other patients remained in a state of isolated RBD (RBDSi). Seven RBDEv (including all those evolving to DLB) and 6 RBDSi patients had MCI at baseline.

Group comparisons of SPECT data at baseline revealed increased rCBF in the hippocampus of RBDEv bilaterally as compared with RBDSi (figure 1 and table e-2). Within RBDEv, no significant difference was observed between those evolving to PD and those converting to DLB.

Correlations at baseline between rCBF and clinical markers associated with the neurodegenerative process were looked across all patients. UPDRS-III positively correlated with rCBF in the right hippocampus (figure 2 and table e-2). UPST-12 positively correlated with rCBF in the medial frontal gyrus (table e-2). FM-100 positively correlated with rCBF in the pons and left hippocampus (figure 3 and table e-2). No significant negative correlation was observed.

Compared with healthy controls, RBDEv showed increased perfusion in the hippocampus bilaterally as well as in the pons (table e-4 and figure e-1). No region displayed significant hypoperfusion in RBDEv compared with controls. Within RBDEv, those evolving to PD displayed increased perfusion in the hippocampus and pons, with additional hyperperfusion of the anterior cingulate cortex, whereas those evolving to DLB had only increased perfusion in the hippocampus. No significant difference of brain perfusion was found in either direction in a comparison of RBDSi with controls.

**DISCUSSION** Our findings demonstrate brain perfusion patterns predicting the appearance of PD or DLB in patients with IRBD. The most consistent brain area associated with this process was the hippocampus. This structure showed increased perfusion in patients with impending conversion, not only when compared with non-evolving IRBD patients but also when compared with control subjects.

Involvement of the hippocampus in the pathophysiology of RBD is supported by both functional and structural brain imaging studies, which suggests a deep reorganization of the hippocampus in RBD. In this study, we demonstrated that hippocampal hyperperfusion was restricted to IRBD patients with future evolution to PD or DLB. Additionally, hyperperfusion of the hippocampus was correlated with worse scores on motor and color-discrimination assessments, 2 parameters associated with the transition to PD. Increased hippocampal perfusion is thus a harbinger of the neurodegenerative process leading isolated RBD to clinical PD or DLB. In
Brain perfusion in the right hippocampus is positively correlated at baseline with UPDRS-III scores across IRBD patients ($p_{corr} < 0.05$). (Left) The 2 panels show the location of this positive correlation in the right hippocampus, on sagittal and coronal sections (from top to bottom), respectively. The level of section is indicated on the top of each panel ($x$, $y$, and $z$ coordinates, in mm). The color scale indicates the range of $t$ values for this contrast. (Right) Plot of the adjusted rCBF responses (arbitrary units) in the right hippocampus ($x = -36$, $y = -12$, $z = -18$) in relation to UPDRS-III scores: rCBF increases when UPDRS-III is higher. Each circle represents 1 subject. The blue line is the linear regression. IRBD = idiopathic REM sleep behavior disorder; rCBF = regional cerebral blood flow; UPDRS = Unified Parkinson Disease Rating Scale.
Brain perfusion in the left hippocampus is positively correlated at baseline with FM-100 scores across IRBD patients ($p_{corr} < 0.05$). (Left) The 2 panels show the location of this positive correlation in the left hippocampus, on sagittal and coronal sections (from top to bottom), respectively. The level of section is indicated on the top of each panel (x and y coordinates, in mm). The color scale indicates the range of t values. (Right) Plot of the adjusted rCBF responses (arbitrary units) in the left hippocampus ($x = -32\, \text{mm}, \, y = -10\, \text{mm}, \, z = -16\, \text{mm}$) in relation to FM-100 scores (adjusted for age and sex, in %). rCBF increases when FM-100 is higher. Each circle represents 1 subject. The blue line is the linear regression. FM = Farnsworth-Munsell; IRBD = idiopathic REM sleep behavior disorder; rCBF = regional cerebral blood flow.

AUTHOR CONTRIBUTIONS

Dr. Dang-Vu contributed to the study concept/design, conducted data analysis and interpretation, and wrote the manuscript. Drs. Montplaisir and Gagnon contributed to the study concept/design, fundraising, and critically reviewed the manuscript. Dr. Postuma contributed to the study concept/design, participated in data collection/analysis, and critically reviewed the manuscript. Mrs. Vendette and Dr. Sooy contributed to the study concept/design and critically reviewed the manuscript.

ACKNOWLEDGMENT

The authors thank Dr. Boualem Mensour for his advice on data analysis and Josie-Anne Bertrand for her help in data collection.

DISCLOSURE

T.T. Dang-Vu receives support from the Canadian Institutes of Health Research, the Belgian Fonds National de la Recherche Scientifique, the Fonds Léon Failliére, and the Belgian College of Neuropsychopharmacology and Biological Psychiatry; and received support from the European Sleep Research Society, the Belgian American Educational Foundation, the Belgian Neurological Society, the Hoellet-Dapsens Medical Foundation, and Wallonie-Bruxelles International. J.-F. Gagnon receives research support from the Canadian Institutes of Health Research (MOP-84482 [PI], MOP-62955 [co-PI], MOP-191058 [co-IL], and MOP-93802 [co-PI]) and Fonds de recherche du Québec–Santé (11834 [PI]). M. Vendette reports no disclosures. J.-P. Sooy receives grants from the Canadian Institutes of Health Research (175519 [co-IL], 191058 [co-IL], 97865 [co-IL], 102631 [co-IL], 245908 [co-IL]), and 115125 [co-PI], 259005 [co-IL], and 97970 [co-IL]) and from a conjoint Canadian Institutes of Health Research/Natural Sciences and Engineering Research Council of Canada program (1004158 [co-IL]). R.B. Postuma receives research funds from the Weston Foundation, the Webster Foundation, the Canadian Institutes of Health Research (201317 [PI], 192205 [co-PI], and 166206 [co-IL]), the Fonds de recherche du Québec–Santé (9965 [PI]), and the Parkinson Society of Canada; and received funds for travel from Allegran and Novartis Canada, and speaker fees from Teva Neuroscience and Novartis Canada. J. Montplaisir receives grants from GlassSmithKline Pharma (PI), from the Canadian Institute of Health Research (15125 [co-IL], 102631 [PI], 166092 [PI], 97865 [co-IL], 62955 [PI], 173519 [co-IL], and 64221 [co-IL], and from Government of Canada Senior Research Chair in Sleep Medicine (PI); and received research grants/support from Merck and GlassSmithKline, served as an advisor for Sanofi-Aventis, Servier, Merck, Jazz

© 2012 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Pharmaceutical, Valeant Pharmaceutical, and Impax Laboratories, and received honoraria for speaking engagements from Valeant Pharmaceutical and Otsuka Pharmaceutical.

Go to Neurology.org for full disclosures.

Received April 25, 2012. Accepted in final form July 27, 2012.

REFERENCES
Hippocampal perfusion predicts impending neurodegeneration in REM sleep behavior disorder
Thien Thanh Dang-Vu, Jean-François Gagnon, Mélanie Vendette, et al.
*Neurology* 2012;79;2302; Published online before print October 31, 2012; DOI 10.1212/WNL.0b013e318278b658

This information is current as of April 10, 2013

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://www.neurology.org/content/79/24/2302.full.html">http://www.neurology.org/content/79/24/2302.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at: <a href="http://www.neurology.org/content/suppl/2012/10/31/WNL.0b013e318278b658.DC1.html">http://www.neurology.org/content/suppl/2012/10/31/WNL.0b013e318278b658.DC1.html</a> <a href="http://www.neurology.org/content/suppl/2012/10/31/WNL.0b013e318278b658.DC2.html">http://www.neurology.org/content/suppl/2012/10/31/WNL.0b013e318278b658.DC2.html</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 10 articles, 4 of which can be accessed free at: <a href="http://www.neurology.org/content/79/24/2302.full.html#ref-list-1">http://www.neurology.org/content/79/24/2302.full.html#ref-list-1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 1 HighWire-hosted articles: <a href="http://www.neurology.org/content/79/24/2302.full.html#related-urls">http://www.neurology.org/content/79/24/2302.full.html#related-urls</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s): Dementia with Lewy bodies <a href="http://www.neurology.org/cgi/collection/dementia_with_lewy_bodies">http://www.neurology.org/cgi/collection/dementia_with_lewy_bodies</a> Parasomnias <a href="http://www.neurology.org/cgi/collection/parasomnias">http://www.neurology.org/cgi/collection/parasomnias</a> Parkinson's disease/Parkinsonism <a href="http://www.neurology.org/cgi/collection/parkinsons_disease_parkinsonism">http://www.neurology.org/cgi/collection/parkinsons_disease_parkinsonism</a> SPECT <a href="http://www.neurology.org/cgi/collection/spect">http://www.neurology.org/cgi/collection/spect</a></td>
</tr>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/misc/about.xhtml#permissions">http://www.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://www.neurology.org/misc/addir.xhtml#reprintsus">http://www.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>